Overview

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Status:
Withdrawn

Trial end date:
2018-10-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the Safety and Efficacy of IONIS-FB-Lrx for up to 120 patients with Geographic Atrophy secondary to Age Related Macular Degeneration

Phase:

Phase 2

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.

Treatments:

Complement Factor B
Complement System Proteins